BiOxyDyn secures funding from early-stage investors

BiOxyDyn, an advanced medical imaging company, has secured £1.2m of investment from two early-stage technology investors.

The investment came from The North West Fund for Biomedical, managed by SPARK Impact, and MTI Venture’s UMIP Premier Fund.

The funding will help BiOxyDyn to expand its imaging service business and to develop its technology into a diagnostic product.